The aim of this study was to determine the effect of heparin thromboprophylaxis during pregnancy on maternal biochemical markers of bone metabolism. This was a prospective longitudinal study of carboxy terminal pro-peptide of type I collagen (PICP) and cross-linked carboxyterminal telopeptide of type I collagen (ICTP) levels in 15 women, who had heparin thromboprophylaxis during pregnancy compared with those of 18 normal pregnant controls. During pregnancy, the rate of change of PICP and ICTP in women who had heparin thromboprophylaxis was similar to those of women who did not (P ¼ 0.184 for PICP, and P ¼ 0.129 for ICTP), and PICP and ICTP levels at individual time points were similar in both groups. Therefore, heparin thromboprophylaxis during pregnancy does not affect maternal biochemical markers of bone metabolism.
INTRODUCTION
Heparin thromboprophylaxis is increasingly being used in pregnancy because it has been shown to improve pregnancy outcome and prevent thromboembolism in women with antiphospholipid syndrome, hereditary thrombophilia or with a previous history of recurrent thromboembolism. 1 -4 In nonpregnant rats heparin treatment for 32 days has been shown to cause osteoporosis by decreasing the rate of bone formation and increasing the rate of bone absorption. 5 Heparin therapy in pregnancy has been found to be associated with a decrease in postpartum lumbar spine bone density. 6 However, there is also a decrease in lumbar spine bone density in normal pregnancies where heparin was not used. 7 It is now possible to directly study bone metabolism by assaying specific biochemical markers of bone turnover. The circulating levels of the carboxy terminal pro-peptide of type I collagen (PICP) directly correlates with the rate of bone formation while the levels of the cross-linked carboxyterminal telopeptide of type I collagen (ICTP) reflects bone resorption. 8 -10 Monitoring these bone markers may reveal subclinical changes in bone metabolism that might indicate a future risk of osteoporosis. Therefore, the aim of this study was to monitor the effect of heparin thromboprophylaxis during pregnancy on the circulating levels of PICP and ICTP.
METHODS
This was a prospective longitudinal study. We studied 15 women who were treated with unfractionated heparin 5000 units twice daily from the date of positive pregnancy test ( performed from day 25 of a 28-day menstrual cycle) till six weeks postpartum between January 2000 and August 2001. The control group consisted of 18 untreated women with uncomplicated pregnancies. We did not perform sample size calculation, but aimed for, and achieved, numbers similar to those used in previous studies on maternal bone metabolism. 11 -13 The indications for heparin therapy included antiphospholipid syndrome (n ¼ 5), previous thromboembolism (n ¼ 4, one with factor V Leiden mutation and one with low antithrombin III), and recurrent miscarriage (n ¼ 4) and previous intrauterine fetal death (n ¼ 2) without antiphospholipid antibodies or thrombophilic defects. All the women conceived spontaneously, and had no history of endocrine, metabolic or renal disease that might have affected their bone turnover. They all gave informed consent to the study, and the study was approved by the hospital's ethics committee.
Seven treated and 12 untreated women were recruited before pregnancy, and blood was obtained prepregnancy and at 6-8, 10-12, 16 -18, 26-28 and 36 -38 weeks gestation and six weeks postdelivery. The blood samples were collected into bottles with lithium heparin, centrifuged immediately and the serum stored at 2208C until analysed in one batch. The serum was analysed for PICP and ICTP by an equilibrium radioimmunoassay (RIA) (DiaSorin, Stillwater, Minnesota, USA). Cross-reaction with the carboxyterminal peptides of other procollagens by the assay kits was minimized by careful purification of the antigen and selection of antiserum.
Samples were incubated with the 125 I PICP/ICTP tracers and PICP/ICTP primary antibodies respectively for two hours at 378C. After separation of bound from free tracer, the assay was centrifuged and decanted. The bound tracer in the pellet was counted with a gamma counter. Counts are inversely proportional to the amount of PICP or ICTP present in each sample. The reference interval for adults aged 20-49 years for PICP is 108 -117 mg/L and for ICTP is 1.6-5.0 mg/L.
Statistical analysis was performed using the Statistics Package for Social Sciences (SPSS). To compare the rate of change during pregnancy between the two groups, analysis of summary measures was made. Linear regression line was fitted for each subject's data to determine the slope that represents the rate of change with gestation (summary measure), and the summary measures were then analysed as though they were raw data. 14 This method is statistically valid and more relevant for medical research data collected serially including variables that start from a baseline (sometimes zero), rise to a peak and then return to baseline, and variables that steadily increase or decrease with time and do not start to return to baseline over the period of the study. 14 The difference in the rate of change PICP and ICTP during pregnancy and circulating levels of PICP and ICTP at the seven individual time points between the women who had heparin thromboprophylaxis and those who did not were assessed using independentsamples t-test.
RESULTS
The age, weight, height, body mass index and parity of the women who had heparin thromboprophylaxis during pregnancy were similar to those of women who did not have heparin thromboprophylaxis (Table 1 ). In the untreated group, the PICP level during pregnancy initially fell and was significantly lower than the prepregnancy level at 10 and 16 weeks (P ¼ 0.038 at 10 weeks and P ¼ 0.034 at 16 weeks gestation). The PICP level subsequently rose and became significantly higher than the prepregnancy level at six weeks postdelivery (P ¼ 0.044) ( Figure 1 ). There was no difference in the PICP levels between the two groups at the individual time points, and the rate of change of PICP in the two groups was similar (P ¼ 0.184).
In the untreated group, the ICTP levels during pregnancy was higher than the prepregnancy levels at all time points, and this rise was significant at 10 and 36 weeks gestation (P ¼ 0.023 at 10 weeks and P ¼ 0.004 at 36 weeks). At six weeks postpartum, the ICTP level was also significantly higher than the prepregnancy levels (P , 0.001) ( Figure 2 ). There was no difference in the ICTP levels between the two groups at the individual time points ( Figure 2 ), and the rate of change of ICTP levels in the two groups during pregnancy was similar (P ¼ 0.129).
DISCUSSION
We have shown that during pregnancy PICP levels initially fall by the second trimester and then rise in the third trimester, rising further in the postpartum period. In contrast, ICTP levels were higher than prepregnancy levels throughout pregnancy and the postpartum period. This is similar to the findings of Ulrich et al. 11 who studied 15 women before, during and after pregnancy and found that the markers of bone formation showed a biphasic pattern with a decrease from prepregnancy to the first (total and bone specific alkaline phosphatase) or second (osteocalcin) trimester, while markers of bone resorption increased with peak levels in the third trimester (N-telopeptides) or postpartum (C-telopeptides). Similarly, Hellmeyer et al. 15 found that the biochemical markers of bone Mean (standard deviation), except parity Ã that is median (range) Comparison was by independent-samples t-test Figure 1 The circulating levels of PICP prepregnancy, during pregnancy and postpregnancy in women who had heparin thromboprophylaxis during pregnancy and those who did not Figure 2 The circulating levels of ICTP prepregnancy, during pregnancy and postpregnancy in women who had heparin thromboprophylaxis during pregnancy and those who did not formation, N-terminal propeptide of type 1 collagen (PINP) showed a significant decrease from the first to the second trimester followed by a significant increase from the second to the third trimester, but another biochemical marker of bone formation, bone alkaline phosphatase and biochemical markers of bone resorption, type 1 collagen C-telopeptide (CTX) and ICTP showed an overall increase from the first to the third trimester. Also, Kaur et al. 16 observed an initial decrease in PINP and CTX and a subsequent rise during pregnancy. Yamaga et al. 12 measured biochemical markers of bone turnover in 18 healthy women throughout pregnancy and observed that both markers of bone formation (intact-osteocalcin and alkaline phosphatase) and bone resorption (tartrate-resistant acid phosphatase, urinary pyridinoline, deoxypyridinoline and hydroxyproline) increased with gestation. Anim-Nyame et al. 13 found that PICP and ICTP levels increased progressively in 17 normal pregnant women, but their study started at 16 weeks gestation when the initial fall in PICP levels may already have occurred. Physiological haemodilution and weight gain of pregnancy may be responsible for the initial decrease in the levels of biochemical markers of bone metabolism demonstrated by some, rather than a true change in bone turnover. 16 But the overall acceleration of bone metabolism demonstrated by this and other studies may reflect the fetal calcium demand that peaks in the third trimester, and maternal calcium decreases as maternal bone resorption peaks in late pregnancy. 11, 17 Short-term high-dose heparin has a temporary effect on bone metabolism characterized by inhibition of osteoblast function as suggested by reduction of serum osteocalcin levels that revert to basal levels four months after completion of anticoagulant therapy. 18 Short-term low-dose heparin has also been associated with a small significant suppressing effect on serum alkaline phosphatase levels (marker of bone formation), but it has no effect on osteocalcin (another marker of bone formation) or the urinary excretion of hydroxyproline and serum ICTP levels (markers of bone resorption). 19 However, in pregnant women confined to bedrest, even short-term unfractionated heparin of 10,000 IU/day induces significant changes in the counter regulatory mechanisms of bone metabolism, particularly a decrease in osteocalcin levels. 20 A potential risk of long-term heparin therapy is osteoporosis, but osteoporosis has not been described when dosages of less than 10,000 IU/day are given or when the treatment period is less than 10 weeks. 19 Heparin therapy in pregnancy has been found to be associated with a decrease in postpartum bone mineral density (BMD). 2, 6, 21 However, Shefras and Farquharson 7 reported a decrease in lumbar spine BMD of 5% during pregnancy in 17 women given low molecular weight heparin (LMWH), but this was not significantly greater than the 3% decrease in a control group of eight untreated pregnant women. Also, Pettila et al. 22 found that the postpartum BMD of the lumbar spine of women who had LMWH (dalteparin) from before 20 weeks gestation till six weeks after delivery was not different from that of healthy postpartum women who did not receive heparin treatment. Therefore, the bone loss associated with the use of long-term LMWH during pregnancy was not significantly different from physiological bone loss that may occur during pregnancy. 23 We used unfractionated heparin as it was the prevalent thromboprophylactic agent at the time of this study. While some studies show lower mean postpartum BMD in women who had unfractionated heparin during pregnancy, compared with those who had LMWH, other studies show similar effect, and overall postpartum BMD remained normal. 22, 24, 25 The studies that showed decreased BMD used higher dosage of unfractionated heparin 21, 22 than that used in this study. Casele et al. 25 found no difference in the change in BMD at the femoral neck or total proximal femur in pregnant women who received a mean dose of 17,380 units unfractionated heparin for a mean of 26.3 weeks compared with those who received a mean of 68.4 mg enoxaparin for a mean of 27.7 weeks. Therefore, the effect of LMWH on PICP and ICTP is likely to be similar to that of unfractionated heparin. LMWH is now commonly used for thromboprophylaxis during pregnancy. LMWH has several well-established advantages over unfractionated heparin including increased bioavailability, more predictable dose response, less intensive coagulation monitoring and a lower probability of causing immunemediated thrombocytopenia. 26 One possible explanation for the failure to demonstrate any difference in either the absolute levels or the rate of change of PICP and ICTP may be the sample size. The study groups were small because of the difficulty in recruiting women to participate in a longitudinal study from preconception to postpartum period. 11 In view of the small numbers, it was not possible to correct for seasonal variation, ethnicity, smoking and breast feeding and this may have influenced the results. Future studies addressing these shortcomings are necessary to confirm our findings.
CONCLUSION
This study is the first to attempt to determine the effect of long-term heparin thromboprophylaxis during pregnancy on these maternal biochemical markers of bone metabolism. We have demonstrated that heparin thromboprophylaxis does not appear to affect the levels of biochemical markers of bone metabolism (PICP and ICTP) during pregnancy, and this supports previous clinical data showing no increased risk of osteoporosis.
This study has provided important longitudinal baseline data for bone biomarkers in pregnancy. Future studies will ideally be large, prospective studies assessing bone biomarkers and parameters such as calcium, parathormone and vitamin D during pregnancy, and bone densitometry before and after pregnancy in women treated with LMWH during pregnancy.
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